Author Archives: admin


Stem Cell Clinic > Articles by: admin

Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients – P&T Community

By Stem Cell Treatment

NESS ZIONA, Israel, Dec. 23, 2019 /PRNewswire/ --Kadimastem Ltd.(TASE: KDST), a clinical stage cell therapy company, today announced that treatment with a single dose of 250x10[6] AstroRxcells to all 5 ALS patients in cohort B has been completed.

The primary objective of the trial is to evaluate the safety of injecting AstroRx, an "off-the-shelf" clinical-grade astrocyte cell product, developed and manufactured by the Company, into the cerebro-spinal fluid (CSF) of ALS patients. A secondary objective of the trial includes preliminary efficacy.

The clinical trial is progressing as planned. Cohort B patients will be monitored for 6 months following treatment.In addition, the first patient of cohort C has already been enrolled. Cohort C is designed to assess long term safety and efficacy of a repeated dose administration of AstroRxin 2 consecutive injections separated by an interval of 2-3 months. As previously reported in September 2019, positive interim results of cohort A demonstrated safety and statistically significant preliminary efficacy of a single dose of 100x10[6] AstroRxcell administration. In light of these positive results, the company is taking the necessary steps to obtain approval to a proposed protocol amendment according to which the repeated administration will comprise of the same dose (100x10[6]).

Results of cohort A and B are expected to be reported as planned and as previously announced, by the end of 2019 and during August 2020, accordingly. Results of cohort C are expected in the first half of 2021.

Rami Epstein, CEO of Kadimastem, commented: "Completing treatment for the additional 5 ALS patients in Cohort B, for a total of 10 patients treated with our product in our clinical trial, serves as an additional demonstration of our ability to develop and produce high quality clinical grade cells and takes us a significant step forward in our path to bringing innovative cure to ALS. The expected completion of cohort B 6-months follow-up period will allow us to assess the safety and preliminary efficacy of 250x10[6]cells, compared to that of the lower dose administered in cohort A."

Prof. Michel Revel, Founder and CSO of the Company, added: "The results of the next treatment group, Cohort C, in which each patient will be treated with 2 consecutive injections separated by an interval of 2-3 months,will allow us to assess the possible prolonged efficacy of the repeated dose, compared to the single dose treatment provided in cohorts A and B. The results that will be obtained from the different cohorts, will support us in the process of defining the dose and treatment regimen that will lead to most favorable results for patients over time."

About AstroRx

AstroRxis a clinical grade cell therapy product developed and manufactured by Kadimastem in its GMP-compliant facility, containing functional healthy astrocytes (nervous system support cells) derived from human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons through several mechanisms of action. The Company's technology enables the injection of AstroRxcells into the spinal cord fluid of patients suffering from Amyotrophic Lateral Sclerosis (ALS) with the goal of supporting the malfunctioning cells in the brain and spinal cord, in order to slow the progression of the disease and improve patients' quality of life and life expectancy. AstroRxhas been shown to be safe and effective in preclinical studies. AstroRxhas been granted orphan drug designation by the FDA.

About ALS

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease causing disfunction in the upper and lower motor nerves that control muscle function. ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is 2-5 years. According to the ALS Therapy Development Institute, it is estimated that there are approximately 450,000 ALS patients worldwide of which 30,000 reside in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to US$ 6 Billion.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic proprietary cell products based on its platform technology for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into clinical grade functional cells. AstroRx, the Company's lead program, is a clinical-grade astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. In addition, preclinical trials are ongoing with the Company's IsletRx pancreatic functional islet cells for the treatment of insulin dependent diabetes. Kadimastem was founded by Prof. Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Prof. Revel received the Israel Prize for the invention and development of Rebif, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Forward Looking Statement

This document may include forward-looking information as defined in the Securities Law, 5728 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developmentsin the general environment and external factors affecting the Company's activity. The Company's results and achievements in the futuremay differ materially from any presented herein and the Company makes no undertaking to update or revise such projectionor estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should take into account that past performance does not necessarily indicate performance in the future.

Company Contacts:

Yossi Nizhar, CFO y.nizhar@kadimastem.com+972-73-797-1604

Investor Relations and Financial Media Meirav Gomeh-Bauer meirav@bauerg.com+972-54-476-4979

Global Media & Collaborations Dasy Mandel, Director of Business Development d.mandel@kadimastem.com +972-73-797-1613

View original content:http://www.prnewswire.com/news-releases/kadimastem-announces-the-completion-of-treatment-for-cohort-b-of-its-phase-12a-clinical-trial-in-als-patients-300979013.html

SOURCE Kadimastem

More:
Kadimastem Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients - P&T Community

Leukaemia and lymphoma have a good survival rate – The Star Online

By Stem Cell Treatment

Of all blood cancers, leukaemia and lymphoma are among the most curable.

However, many people, including doctors, still believe the disease leads to immediate death.

This is no longer true today as they are not fatal.

With optimal treatment, the majority of patients go into remission and are considered cured.

These two cancers have been more extensively studied than other forms of cancer, due to the ease in obtaining samples from blood, bone marrow or lymph nodes, spurring the advent of novel targeted therapies for a cure, says consultant haematologist Dr Ng Soo Chin.

Most blood cancers start in the bone marrow, where blood is produced.

Bone marrow contains stem cells, which mature and develop into red blood cells, white blood cells or platelets.

In most blood cancers, normal cell development is interrupted by the uncontrolled growth of an abnormal type of a particular blood cell.

These abnormal blood cells, which are cancerous, prevent your blood from performing many of its functions, like fighting off infections or preventing serious bleeding.

Leukaemia or white blood is classified into acute and chronic disease, which is then divided further into subtypes: acute lymphocytic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML).

The presentation between acute and chronic leukaemia differs.

The acute person will tell you he was well a week ago and is now down with symptoms such as lethargy, anaemia and recurrent infection.

Suddenly, he may look pale, so we check his blood count for any abnormalities. A bone marrow exam will further confirm whether it is acute.

With chronic leukaemia, the patient can be unwell for a couple of months.

We are increasingly picking up cases early because of blood test availability.

The survival rate has improved tremendously for acute leukaemia, with more than 50% fully cured because bone marrow transplants are easily available in the country.

For CLL and CML, 95% of patients are alive at the 10-year mark, says Dr Ng.

Generally, chronic leukaemia patients belong to the older age group (50 years and above), but acute leukaemia can occur in all ages.

Leukaemia symptoms are often vague and not specific, so its easy to overlook them as they may resemble symptoms of the flu and other common illnesses.

In fact, chronic leukaemia may initially produce no symptoms and can go unnoticed or undiagnosed for years.

Lymphomas, a type of blood cancer that begins in a subset of white blood cells called lymphocytes, can be classified into Hodgkins and non-Hodgkins.

The main difference between Hodgkins and non-Hodgkins lymphoma is the specific lymphocyte each involves.

Lymphocytes are an integral part of your immune system, which protects you from germs.

Five-year survival rates are high with Hodgkins lymphoma at 86% and non-Hodgkins lymphoma at 70%.

You can beat the disease even if it is detected at a late stage.

Multiple myeloma, which is the third kind of blood cancer, forms in a type of white blood cell called a plasma cell.

Patients often complain of bone pain, and unfortunately, this type of cancer has no cure.

Blood cancers typically involve abnormal white blood cells and can affect paople of all ages, depending on the type of cancer. 123rf.com

Fear of treatment

Chemotherapy is a much dreaded word among cancer patients.

But with advances in medicine, newer chemotherapy-free treatments are now available.

Dr Ng says, Traditionally, cancer is treated via surgery or radiation the layman says we fry and poison them, which is not far from the truth!

Radiation means burning the cancerous area, but a lot of times, the cancer can also be present elsewhere, so there is limitation to this treatment.

With chemotherapy, we use cytotoxic (cell-killing) drugs they go in and knock off both cancer and normal cells.

The short-term effects include vomiting, hair loss, appetite loss and weight loss.

But as doctors, we are looking at a different perspective. We are more worried about white cells dropping (neutropenia) because the patient can pick up an infection that can potentially kill him.

Neutropenia is a condition that results when the body does not have enough neutrophils, a type of white blood cell that is an essential first line of defence against infections.

Thats one risk of chemotherapy, although we can now improve neutropenia by giving a growth factor injection.

But for certain cancers, we need to step up the drugs.

He adds: We are scared of neutropenia, but patients are more concerned about bodily changes.

The older ones get upset over losing hair because they cannot take it when others ask them what has happened to their hair.

Young people are not as concerned with hair loss because it can be trendy.

We understand that chemotherapy is less than pleasant and strong doses can impair fertility in young patients, especially women.

Despite current technology, only one-third of patients are successful in freezing their eggs.

What he is concerned about is that chemotherapy can actually increase the patients risk of getting another cancer, especially blood cancer.

It can happen the day after! says Dr Ng.

Most experts believe chemotherapy damages stem cells, so if youre unlucky, you might get acute myeloid leukaemia after undergoing chemotherapy for breast cancer.

Its just like crossing the road there is always a risk of being knocked down.

All our cells have a biological clock and there is an orderly exchange of old and new cells.

But with blood cancers such as leukaemia, there is a clone of abnormal cells.

Cancer cells have an advantage over normal cells because they can survive longer.

Chemotherapy is still needed to treat most acute blood cancers, although if the mutation is known, targeted therapies can be applied.

For chronic blood cancers, there is no need for chemotherapy. Oral drugs are enough to combat the disease.

Eventually, many patients are able to wean off the drugs.

As we may be aware, immunotherapy is the buzzword in cancer treatment today.

Also called biologic therapy, it is a type of cancer treatment that boosts the bodys natural defences to fight cancer.

It uses substances made by the body or in a laboratory to improve or restore immune system function.

One of the latest treatment modalities is the CAR T-cell therapy, a form of immunotherapy that uses specially altered T cells a part of the immune system to fight cancer.

A sample of a patients T cells are collected from the blood, then modified to produce special structures called chimeric antigen receptors (CARs) on their surface.

When these CAR T-cells are reinfused into the patient, the new receptors enable them to latch onto a specific antigen on the patients tumour cells and kill the cells.

At the moment, this intravenous therapy is available in the United States and hasnt reached our shores yet. It has to be properly regulated first, says Dr Ng.

A volunteer is having his head shaved to donate hair to make wigs for cancer patients in this filepic. Hair loss is one of the side effects of chemotherapy that affect patients the most.

Following natural remedies

The consultant haematologist errs on the side of caution when patients ask about natural cancer remedies, or the dos and donts during treatment.

We always believe there should be a scientific approach to the problem.

If patients are doing okay while undergoing treatment and there is no weight loss, I tell them to go ahead and do what they always do.

However, just be particular about food hygiene, as there is a chance you may get food poisoning.

If youre undergoing chemotherapy, then youll land yourself in hospital, and if your luck is bad, you may even land up in the ICU (intensive care unit).

So make sure the food is cooked and not left overnight to reduce your chances of infection.

Eat a balanced diet, he advises.

When it comes to exercise, he says to work out within your limit.

Instead of pushing the body and running marathons or climbing mountains, go for walks.

Dr Ng says, Life should go on, but be sensible.

Dont go to crowded places because you may pick up an infection, but dont be withdrawn either. All humans need social interaction.

With the billion-dollar dietary supplements industry, companies are constantly trying to lure customers into buying their products.

A lot of supplements are just glorified vitamins in different packaging.

The more expensive they are, the more people will buy them, thinking they are good.

There are people with good intentions, but unfortunately, there are also a lot of scammers out there that is life.

For the amount you spend on supplements, why not keep the money aside and go for a trip once your treatment is over? he suggests.

Often, the late diagnosis is due to preference for alternative treatment.

These alternative treatments are like fashion shows, after some time, they go out of trend.

For me, youre wasting valuable time because cancer is not your friend.

Yes, chemotherapy is tough, but with the latest chemo-free regimen, patients are more willing to come forward.

The earlier it is treated, the higher your chances of recovering, he says.

To share his 30-odd years of knowledge and experience in the field, Dr Ng has written his third book titled Understanding Blood Disorders.

Intended for patients, caregivers and healthcare professionals, proceeds from the sales of the 270-page book will go to the newly set-up Faith Hope Love Hospice Care Malaysia in Petaling Jaya, Selangor.

We're sorry, this article is unavailable at the moment. If you wish to read this article, kindly contact our Customer Service team at 1-300-88-7827. Thank you for your patience - we're bringing you a new and improved experience soon!

Article type: metered

User Type: anonymous web

User Status:

Campaign ID: 7

Cxense type: free

User access status: 3

Visit link:
Leukaemia and lymphoma have a good survival rate - The Star Online

Pike River widow credits granddaughter with getting her through cancer ‘battle’ – Stuff.co.nz

By Stem Cell Treatment

Pike River widow Anna Osborne is creditingher granddaughter withhelpingher get through invasive cancer treatment.

Osborne, whose husband Milton died West Coastmine disaster just over nine years ago, had stem-cell replacementforHodgkinlymphoma in October.

She was told she had a four weeksto a year to live without the risky surgery, or up to five years with it. Wanting to see 2-year-old grandaughter Amalia start school was a big factor in thedecision to push ahead.

Supplied

Anna Osborne and her two-year-old granddaughter, Amalia, who Osborne says has been her inspiration to prolong her life after fighting cancer.

Her stem-cells wereharvested and frozenin August. The stem cell transplanttook place in Christchurch in October aftersix days of intensive chemotherapy.

READ MORE:*Pike River mine tunnel entry an important moment for widow*Pike River re-entry team breaks through into mine drift*Pike River widow 'full of nerves' for mine drift re-entry*The road to getting back into Pike River

"It kills everything.It was pretty rough going," Osborne told Stuff from herhospital bed in Greymouth.

Joanne Carroll/Stuff

Osborne has undergone a stem cell transplant, but has been in and out of hospital during her recovery.

"It was a long and really difficult process because I became really really ill. Vomiting, sleeping all the time. If I caught an infection it could kill me."

After the successful transplant of her stem-cells back into her body, she stayed in Christchurch'stransplant unit forfive weeks.

She was then transferred to Grey Base Hospital.

Phil Walter/Getty

Osborne greeting Prime Minister Jacinda Ardern when the Pike River re-entry got under way in May.

"I've been home threetimes from hospital, only two days each time. On the second day, I've just gone right down again and got nothing left to give,so I'm backin hospital. It's been a bit of a battle."

She has no appetite, is nauseousand and unable to retain some nutrients.

"My bloods might be normal but then very quickly I can't retain any electrolytes and I go down hill and everything is depleted.

Kevin Stent/Stuff

Osborne, left, with friend and fellow Pike River family member Sonya Rockhouse.

"It's a hard road. You're sick of being sick ...sick of having no energy.

"I know in the end it's going to be worthwhile and I've bought myself another four or five years. Hopefully a lot longer than that."

Osbornewasdiagnosed with the cancer, which attacks theimmune system,in 2002 at age 36.

Stacey Kirk/Stuff

Representatives of some of the Pike River families - Anna Osborne, Sonya Rockhouse and Bernie Monk - talk of their elation at the decision to re-enter the mine. (First published November 2018)

She had radiation for six weeks and went into remission, but the cancercame back just before the Pike River tragedy in November 2010, when 29 men where killed in a series of explosions at the coal mine. Osborne helped campaign for thelegalisation of medicinal cannabiswhile undergoing chemotherapy in 2015.

She is awaiting a full scan to see if the treatment has removed all the tumours in her body. For now, she is taking each day as it comes.

"I'm feeling quite positive. I've got four or five years left in me. You've got to remain positive. It's easy to give up," she said.

At her darkest moments, Amalia was at the forefront of her mind.

"She needs me and I need her. I want to be there when she starts school. She was the person that got me through and made me want to keep going.

"She's magnificent. She's brightened my world ... it's really nice having her to keep going for."

Osborne said she had a special bond with Amalia.

"She will bring her blankie and baby and sit on my lap and just cuddle into me, and my daughter says she doesn't do that for anyone.

"I can't give up on that,it's too beautiful."

Link:
Pike River widow credits granddaughter with getting her through cancer 'battle' - Stuff.co.nz

Study of the 3D Cell Culture Market in Asia-Pacific, 2019-2027: Projecting a 13.11% CAGR, Driven by Promising Developments Using Regenerative Medicine…

By Stell Cell Research

Dublin, Dec. 23, 2019 (GLOBE NEWSWIRE) -- The "Asia-Pacific 3D Cell Culture Market 2019-2027" report has been added to ResearchAndMarkets.com's offering.

Research conducted shows the 3D cell culture market in the Asia-Pacific would be fast progressing in terms of revenue, with a CAGR of 13.11% over the forecasting years 2019-2027.

India, Japan, China, South Korea, Australia & New Zealand, ASEAN countries and Rest of APAC countries together constitute the Asia-Pacific 3D cell culture market.

Several R&D projects are being initiated in South Korea to cater to the rising demand for stem cell therapies and regenerative medicine. In September 2017, the Cell Therapy World Asia 2017 was held in the country. Several cell therapy companies in Asia gathered for the conference to discuss the best practices & innovations in this field. Such factors are promoting the growth of the South Korean 3D cell culture market.

It has been anticipated that the 3D cell culture market in Japan would witness growth, owing to the country releasing new products in the market. Pluristem Therapeutics received a patent for their technology of using 3D cell culturing methods, that allow the creation of cell therapies from fat cells.

The Government of Japan has been focusing increasingly on Cell-based regenerative medicine, which indicates further advances in 3D cell culture technology over the projected period. In 2014, Japan-based Reprocell acquired Reinnervate Ltd., a spin-off of Durham University, agreeing to invest in the researches conducted in the university laboratories for scaffolding structures that support the growth of 3D cells.

COMPETITIVE OUTLOOK

The biggest brands in the 3D cell culture market are Merck KGaA, 3D Biotek, LLC, Thermo Fisher Scientific, Inc., Corning Inc., InSphero, Lonza Group AG, and Synthecon, Incorporated.

Key Topics Covered

1. Asia-Pacific 3D Cell Culture Market - Summary

2. Industry Outlook

2.1. Market Definition2.2. Porter'S Five Forces Model2.2.1. Threat Of New Entrants2.2.2. Threat Of Substitute2.2.3. Bargaining Power Of Buyers2.2.4. Bargaining Power Of Suppliers2.2.5. Threat Of Competitive Rivalry2.3. Economic Technological, And Political & Legal Outlook2.4. Regulatory Outlook2.5. Key Insight2.6. Market Attractiveness Index2.7. Market Drivers2.7.1. Growing Cancer Prevalence2.7.2. High Demand For Organ Transplantation2.7.3. Promising Developments Using Regenerative Medicine2.8. Market Restraints2.8.1. Lack Of Skilled Professionals2.8.2. Incompatibilities Of The Preferred Analytical Technologies With 3D Cell Culture2.9. Market Opportunities2.9.1. Increasing Usage Of 3D Cell Culture In Organ Transplantation And Drug Screening2.9.2. Technological Advancement2.10. Market Challenges2.10.1. Lack Of Availability Of Data For Research On 3D Cell Culture2.10.2. Challenges Associated With 3D Cell Culture In Performing Experiments

3. 3D Cell Culture Market Outlook - By Technology

3.1. Scaffold-Based3.1.1. Hydrogels3.1.2. Polymeric Scaffolds3.1.3. Micropatterned Surface Microplates3.2. Scaffold-Free3.2.1. Hanging Drop Microplates3.2.2. Spheroid Microplates Containing Ultra-Low Attachment (Ula) Coating3.2.3. Microfluidic 3D Cell Culture3.2.4. Magnetic Levitations & 3D Bioprinting3.3. 3D Bioreactors

4. 3D Cell Culture Market Outlook - By Application

4.1. Cancer4.2. Tissue Engineering & Immunohistochemistry4.3. Drug Development4.4. Stem Cell Research4.5. Other Applications

5. 3D Cell Culture Market Outlook - By Component

5.1. Media5.2. Reagents And Consumables

6. 3D Cell Culture Market Outlook - By End-User

6.1. Biotechnology And Pharmaceutical Organizations6.2. Research Laboratories And Institutes6.3. Hospitals And Diagnostic Centers6.4. Other End-Users

7. 3D Cell Culture Market - Regional Outlook

7.1. Asia-Pacific7.1.1. Country Analysis7.1.1.1. Japan7.1.1.2. China7.1.1.3. India7.1.1.4. Australia & New Zealand7.1.1.5. South Korea7.1.1.6. Asean Countries7.1.1.7. Rest Of Asia-Pacific

8. Company Profiles

8.1. Becton Dickinson And Company8.2. Tecan Group Ltd.8.3. Promocell Gmbh8.4. Corning Inc.8.5. Nano3D Biosciences, Inc.8.6. 3D Biotek, Llc8.7. Merck Kgaa8.8. Emulate8.9. Thermo Fisher Scientific, Inc.8.10. Ge Healthcare8.11. Insphero8.12. Lonza Group Ag8.13. Vwr Corporation8.14. Synthecon, Incorporated

For more information about this report visit https://www.researchandmarkets.com/r/reo3ym

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Visit link:
Study of the 3D Cell Culture Market in Asia-Pacific, 2019-2027: Projecting a 13.11% CAGR, Driven by Promising Developments Using Regenerative Medicine...

Stem Cells Market Poised to Expand at a Robust Pace Over 2017 to 2025 – Market Research Sheets

By Stell Cell Research

In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This post was originally published on Market Research Sheets

Continue reading here:
Stem Cells Market Poised to Expand at a Robust Pace Over 2017 to 2025 - Market Research Sheets

Illuminating Christmas, 19 years and counting… in honour of the Anthony Nolan Charity – London News Online

By Stell Cell Research

The magic of Christmas comes in the form of fairy lights this year and stem cells.

Retired taxi driver Gunaltay Mustafa has illuminated his house with a 1,000-bulb Christmas display for the 19th year in a row.

The aim of his festive lights is to raise funds and awareness for Anthony Nolan, the charity that saved his sons life.

Anthony Nolan works to find matching stem cell donors for people with blood cancer and blood disorders.

Gunaltays son, Alex, was diagnosed with leukemia when he was four.

After three years of treatment he went into remission. When he was just 11, his leukemia returned for the second time.

Anthony Nolan searched the stem cell register and was able to find Alex a lifesaving stemcell match.

Thanks to the donor that was found by Anthony Nolan, Alex is now a healthy 24-year-old with his whole life ahead of him.

Mustafa said: Everyone in the area knows about the Christmas light house, and this year we have more lights than ever before.

The display brings a bit of Christmas cheer to Southwark every year, with the added intention of giving a little something back to Anthony Nolan.

It costs 40 for Anthony Nolan to add each new donor to the register, so the charity needs financial support to help it continue to give patients, their family and friends hope.

The charity also carries out pioneering research to increase stem cell transplant success, and supports patients through their transplant journeys.

Senior community fundraiser at Anthony Nolan, Beatrix Passmore, said: In raising funds and awareness, Gunaltay will help Anthony Nolan give blood cancer patients, like his son Alex, a second chance of life.

Excerpt from:
Illuminating Christmas, 19 years and counting... in honour of the Anthony Nolan Charity - London News Online

The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018 – Yahoo Finance

By Stell Cell Research

NEW YORK, Dec. 23, 2019 /PRNewswire/ -- The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018. The market is estimated to grow with a CAGR of 16.2% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05833602/?utm_source=PRN

Driving factors of the in vitro lung model are significant growth in research funding, and increasing adoption of 3d model systems for in vitro studies.Also, growing research on lung diseases is likely to have a positive impact on the growth of the market in the coming years.

Besides, rising healthcare expenditure, and advancements in cell culture techniques is likely to have a positive effect on the growth of the market in the forecast years.The cases of asthma, lung cancer, and COPD has been growing across the globe at a significant rate.Thus there is a growing need to study lung diseases specifically.

Since early 2010's the practices of creating lab-grown organ buds, mostly referred to as 'organoids', have become more popular.These organ buds are miniature organ-like structures that are maintained in the lab, and researchers are able to grow these organoids, which resembles human body tissues.

Lung diseases, like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), is a significant cause of death and illness worldwide.A recently published report by Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California developed a new system for building lung 3D organoids to model lung disease.

Moreover, Lung cancer cell lines have made a significant contribution to lung cancer research and biomedical discovery. The high similarities between lung cancer cell lines and the lung tumor helps in discovering new drug molecules. Thus the growing research on lung diseases is expected to offer broad growth opportunities for the in vitro lung model market at the global level.The global in vitro lung model market is segmented by type, and application.On the basis of type, the market is segmented into 2D and 3D.

The 3D segment is expected to dominate the type segment market as 3D cell culture gives better phenotypes insights which are poorly reproduced in conventional 2D cell culture, Based on the application, market is segmented into drug screening, toxicology, 3d model development, physiologic research, stem cell research, and regenerative medicine. Toxicology segment is expected to dominate the application segment during the forecast period.Some of the important primary and secondary sources included in the report are, Food and Drug Administration, World Health Organization (WHO), American Society of Clinical Oncology, American Type Culture Collection, Centers for Disease Control and Prevention, Canadian Lung Association and others.

Read the full report: https://www.reportlinker.com/p05833602/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-in-vitro-lung-model-market-is-expected-to-reach-us-701-81-mn-in-2027-from-us-185-80-mn-in-2018--300978999.html

SOURCE Reportlinker

Read the rest here:
The global in vitro lung model market is expected to reach US$ 701.81 Mn in 2027 from US$ 185.80 Mn in 2018 - Yahoo Finance

Global and Southeast Asia Embryonic Stem Cell Market 2013-2023 by Top Key Players, YoY Growth, Trends, Size, Share and Revenue Analysis – Market…

By Stell Cell Research

Kenneth Research recently published a detailed report on Global and Southeast Asia Embryonic Stem Cell Market which focuses on various market dynamics by providing in-depth details of the key market outlook factors, such as, market size and forecast, market segmentation and others for the forecast period 2013-2023. The report on Embryonic Stem Cell Market further portrays elaborated structure of the market which comprises of all necessary business-related information at global and regional levels. The information for the Embryonic Stem Cell Market is obtained from various sources, which are arranged and formulated according to the business need by our team of analysts and editors through the application of different methodological techniques and analytical tools, for instance, SWOT, PESTEL and others.

Request for Sample Copy of Business Report:https://www.kennethresearch.com/sample-request-10035836

The report also describes the key growth factors, drivers, opportunities and restraints, and depicts the competitive scenario of the Embryonic Stem Cell Market with detailed information regarding the segment of the market by Product, Trends, Technology, Top Key Players of Global Market, Distributors, Demand, Supply, Revenue and Sales Analysis and focuses on key statistics which includes market size and market value, Y-o-Y growth rate, CAGR, market share and others.

The report on Embryonic Stem Cell Market further examines the region wise growth for North America, Europe, Asia Pacific, Latin America and Middle East & Africa region and is further classified into:

Request for Sample Copy of Business Report:https://www.kennethresearch.com/sample-request-10035836

Competitive Analysis for Embryonic Stem Cell Market:

The leading key players studied in the Embryonic Stem Cell Market report includes Major Key Players of Global Market. These players are extensively engaged in the expansion of their customer base by implementing various strategies and ensuring ongoing process improvements, along with added investments for research and developments, so as to gain an extra edge in the competition.

Table of Content:

Chapter One Introduction of Embryonic Stem Cell Industry

Chapter Two Manufacturing Technology of Embryonic Stem Cell

Chapter Three Analysis of Global Key Manufacturers

Chapter Four 2013-2018 Global and Southeast Asia Market of Embryonic Stem Cell

Chapter Five Market Status of Embryonic Stem Cell Industry

Chapter Six 2018-2023 Market Forecast of Global and Southeast Asia Embryonic Stem Cell Industry

Chapter Seven Analysis of Embryonic Stem Cell Industry Chain

Chapter Eight Global and Southeast Asia Economic Impact on Embryonic Stem Cell Industry

Chapter Nine Market Dynamics of Embryonic Stem Cell Industry

Chapter Ten Proposals for New Project

Chapter Eleven Research Conclusions of Global and Southeast Asia Embryonic Stem Cell Industry

Tables and Figures Cont.

Request for Complete Details of This Business Report:https://www.kennethresearch.com/sample-request-10035836

About Kenneth Research:

Kenneth Research provides an extensive multi-client market research database with a non-exhaustive list of market research solutions that are aimed to meet the market demands of its clients across industry verticals, such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. One of the best rated reselling agencies for market research reports, our product portfolio includes key insights such as market sizing and market forecasting, market share analysis and key positioning of the players. Our team of analysts deliver their best expertise to enhance the knowledge of industry veterans and investors within the stipulated time for efficient strategy formulation and maximization of opportunity benefit.

Trending New Reports:

Chicory MarketChemotherapy-Induced Nausea and Vomiting (CINV) MarketChampagne MarketCell and Tissue Culture Supplies MarketCAT Scanner MarketCardiac Rhythm Management Devices MarketCancer Antibody Drug Conjugates MarketButter MarketBubble Milk Tea MarketBrewers Peptone Market

This post was originally published on Market Research Sheets

More:
Global and Southeast Asia Embryonic Stem Cell Market 2013-2023 by Top Key Players, YoY Growth, Trends, Size, Share and Revenue Analysis - Market...

Researchers Create Functional Mini-Liver by 3D Bioprinting – 3D Printing Progress

By Stell Cell Research

Using human blood cells, Brazilian researchers have succeeded in obtaining hepatic organoids ("mini-livers") that perform all of the liver's typical functions, such as producing vital proteins, storing vitamins, and secreting bile, among many others. The innovation permits the production of hepatic tissue in the laboratory in only 90 days and may in the future become an alternative to organ transplantation.

The study was conducted at the Human Genome and Stem Cell Research Center (HUG-CELL). Hosted by the University of So Paulo (USP), HUG-CELL is one of the Research, Innovation and Dissemination Centers (RIDCs) funded by So Paulo Research Foundation - FAPESP.

"More stages have yet to be achieved until we obtain a complete organ, but we're on the right track to highly promising results. In the very near future, instead of waiting for an organ transplant, it may be possible to take cells from the patient and reprogram them to make a new liver in the laboratory. Another important advantage is zero probability of rejection, given that the cells come from the patient," said Mayana Zatz, director of HUG-CELL and last author of the article published in Biofabrication.

The innovative part of the study resided in how the cells were included in the bioink used to produce tissue in the 3D printer. "Instead of printing individualized cells, we developed a method of grouping them before printing. These 'clumps' of cells, or spheroids, are what constitute the tissue and maintain its functionality much longer," said Ernesto Goulart, a postdoctoral fellow in USP's Institute of Biosciences and first author of the article.

The researchers thereby avoided a problem faced by most human tissue bioprinting techniques, namely, the gradual loss of contact among cells and hence loss of tissue functionality.

Spheroid formation in this study already occurred in the differentiation process, when pluripotent cells were transformed into hepatic tissue cells (hepatocytes, vascular cells, and mesenchymal cells). "We started the differentiation process with the cells already grouped together. They were cultured in agitation, and groups formed spontaneously," Goulart told Agncia FAPESP.

A liver in 90 days

The next stage consists of inducing differentiation into liver cells. The spheroids are then mixed with bioink, a hydrogel-like fluid, and printed out. The resulting structures mature in culture for 18 days.

"The printing process entails the deposition of spheroids along three axes, which is necessary for the material to gain volume and give the tissue proper support," Goulart said. "The gel-like bioink is crosslinked to make the structures more rigid so that they can be manipulated and even sutured."

Most of the available methods for printing live tissue use immersion and cell dispersion in a hydrogel to recapitulate the microenvironment and ensure tissue functionality. However, experiments have shown that loss of cell contact and functionality tends to occur when dispersion is performed cell by cell.

"It's a somewhat traumatic process for the cells, which need time to get used to the environment and acquire functionality," Goulart said. "At this stage, they aren't tissue yet because they're dispersed, but as shown by our study, they already have the capacity to clear the blood of toxins and to produce and secrete albumin (a protein produced only by the liver), for example."

In this study, researchers developed mini-livers using blood cells from three volunteers as raw material and compared markers relating to functionality, such as the maintenance of cell contact and protein production and release. "Our spheroids worked much better than those obtained from single-cell dispersion. As expected, during maturation, the markers of hepatic function were not reduced," Goulart said.

Although the study was limited to producing miniature livers, the technique can be used in the future to produce complete organs suitable for transplantation, according to Goulart. "We did it on a small scale, but with investment and interest, it can easily be scaled up," he said.

Source and top image: Fundacao de Amparo A Pesquisa Do Estado De Sao Paulo

Read more here:
Researchers Create Functional Mini-Liver by 3D Bioprinting - 3D Printing Progress

FY 2020 Government Funding Bill Repeals ACA Health-Related Taxes, Extends Expiring Health Provisions, Makes Other Health Policy Updates – Lexology

By Stell Cell Research

Congress has completed action on federal fiscal year (FY) 2020 spending, and President Trump has signed the two domestic and national security funding packages into law. The major health care policy provisions included in the domestic spending package, HR 1865, the Further Consolidated Appropriations Act, 2020 (the Act), are summarized below.

Repeal of ACA Device, Insurance Taxes

The Act permanently repeals the Affordable Care Acts (ACA) 2.3% excise tax on the sale of certain medical devices, which has been a top priority of the medical technology industry. It also permanently repeals the excise tax on certain high-cost employer-sponsored health coverage (the so-called Cadillac tax) and the annual excise tax imposed on health insurer providers.

Medicare Part B Policies

The Act incorporates provisions of the Laboratory Access for Beneficiaries (LAB) Act, which delays the next round of clinical laboratory private payer data reporting for one year. The Act also directs the Medicare Payment Advisory Commission (MedPAC) to study how to improve this data collection.

In addition, the Act excludes certain complex rehabilitative manual wheelchairs (e.g., HCPCS codes E1235, E1236, E1237, E1238, and K0008) from the Medicare durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) competitive bidding program. The Act also bars CMS from using competitive bidding rate information to adjust payment for certain wheelchair accessories and cushions furnished with complex rehabilitative manual wheelchairs.

The Act reimburses acute care hospitals on a reasonable cost basis for furnishing allogeneic hematopoietic stem cell transplants. It also extends outpatient hospital pass-through status for a number of diagnostic radiopharmaceuticals.

Medicare, Medicaid, and Public Health Extenders

The Act extends through May 22, 2020 a number of Medicare, Medicaid, and public health programs and policies, including the following:

In addition, the Act funds the Patient-Centered Outcomes Research Trust Fund through 2029, with a requirement that research projects consider a broader range of outcomes data and an expansion of research priorities to include research with respect to intellectual and developmental disabilities and maternal mortality. The Act also establishes Medicaid funding policy for the territories through FY 2021.

Other Health Policies

Other policies addressed by the Act include, among others:

Note that the Statement of Managers accompanying the Act also includes nonbinding requests that CMS review a wide range of reimbursement and other policies, such as air ambulance policy, reimbursement for innovative drugs, inefficiencies in the Recovery Audit program, telehealth coding, CMS innovation models, and Medicare Part D performance metrics.

Read more here:
FY 2020 Government Funding Bill Repeals ACA Health-Related Taxes, Extends Expiring Health Provisions, Makes Other Health Policy Updates - Lexology

→←